Upsher-Smith Laboratories LLC, a subsidiary of Bora Pharmaceuticals Co Ltd (TW:6472 and OTCQX:BORAY), announced on Wednesday that it has launched its Cyclosporine Ophthalmic Emulsion 0.05%, therapeutically equivalent to the Reference Listed Drug (RLD), RESTASIS (cyclosporine ophthalmic emulsion) 0.05%.
Cyclosporine ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
According to IQVIA, the US market for cyclosporine ophthalmic emulsion generated sales of approximately USD1.9bn in the 12 months from February 2025 to January 2026.
Bora received US Food and Drug Administration (FDA) approval of its abbreviated new drug application (ANDA) for the product in January 2026.
AstraZeneca reports third positive Phase III trial for tozorakimab in COPD
GSK strengthens pulmonary hypertension pipeline with USD950m acquisition of 35Pharma
Mestag Therapeutics to present targeted LTBR agonist MST-0312 at AACR Annual Meeting
EU approves Sanofi and Regeneron's Dupixent for young children with chronic spontaneous urticaria
GSK secures China approval for Exdensur to treat nasal polyp condition
Insmed reports Phase 2b study of brensocatib did not meet efficacy endpoints
Alloy Therapeutics and Biogen expand partnership with multi-target antisense collaboration
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
Boston Scientific receives FDA clearance for Asurys fluid management system
Lilly presents Phase 3b Taltz (ixekizumab) plus Zepbound (tirzepatide) data at AAD Annual Meeting
Hoth Therapeutics deploys OpenClaw AI platform for drug discovery
Thermo Fisher Scientific and SHL Medical launch integrated US drug-device manufacturing